科拓生物(300858) - 300858科拓生物业绩说明会20250508

Group 1: Industry Outlook - The domestic probiotic raw material market is dominated by multinational companies like DuPont and Chr. Hansen, which together hold over 80% market share, indicating a need for increased market share of domestic strains [1] - With technological breakthroughs in China, domestic alternatives are becoming a trend, providing a competitive edge for companies with proprietary strains and rigorous scientific validation [1][3] Group 2: Company Performance - The overall performance of the probiotic industry is strong, driven by increasing consumer health awareness and the rapid growth of functional food markets [3] - In 2024, the company achieved a revenue of 302.79 million yuan, a year-on-year increase of 1.19%, with the edible probiotic product segment growing by 20.85% [4] - The net profit attributable to the parent company was 94.36 million yuan, reflecting a year-on-year growth of 0.94% [4] Group 3: Future Growth Drivers - The edible probiotic product segment is the largest revenue contributor and has the strongest profitability, representing a significant growth point for the company [3] - The company plans to increase R&D investment, optimize sales channels, and enhance brand influence to expand market share [3]